Nonetheless, the use of small-molecule compounds to modulate IDO1/2, TDO2, and AhR in glioma and meningioma cell lines has already proven that in contrast to enzyme inhibition, AhR antagonists markedly reduce tumor cell viability, i.e., AhR may be a therapeutic target in these types of cancer. This evidence concerns the gene IDO1 and neoplasm.